Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

milameline

Known as: 1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxaldehyde O-methyloxime monohydrochloride 
 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

CI 979

Broader (2)

DihydropyridinesOximes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Combined cerebral blood flow effects of a cholinergic agonist (milameline) and a verbal recognition task in early Alzheimer’s disease
Abstract  RU 35926/CI‐979 (milameline) is a partial muscarinic agonist with promnestic effects in animal models. Preliminary… Expand
2006
2006
Milameline: Nonselective, Partial Muscarinic Receptor Agonist for the Treatment of Alzheimer's Disease?
Alzheimer’s disease (AD) is a neurodegenerative disorder clinically characterized by a progressive loss of cognitive functions… Expand
  • figure 1
  • table 2
  • table 3
Highly Cited
2005
Highly Cited
2005
Pharmacologic Interactions between the Muscarinic Cholinergic and Dopaminergic Systems in the Modulation of Prepulse Inhibition in Rats
Prepulse inhibition (PPI) of the acoustic startle reflex is a sensorimotor gating process known to be deficient in a number of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • table 1
Highly Cited
2003
Highly Cited
2003
MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD
Objective: To assess the feasibility of using MRI measurements as a surrogate endpoint for disease progression in a therapeutic… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Highly Cited
2000
Highly Cited
2000
Interrater Reliability of the Clinical Dementia Rating in a Multicenter Trial
OBJECTIVE: To test the interrater reliability of the Clinical Dementia Rating (CDR) in a multicenter clinical trial. 
Highly Cited
1999
Highly Cited
1999
Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.
The purpose of our studies was to determine the effects of muscarinic receptor agonists on conditioned avoidance responding in… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
1999
1999
Muscarinic Receptor Agonists in Alzheimer’s Disease
Research into and development of selective muscarinic receptor agonists for the treatment of Alzheimer’s disease is based on the… Expand
1999
1999
Combining tacrine with milameline reverses a scopolamine-induced impairment of continuous performance in rhesus monkeys
Abstract  Rationale: Cholinomimetic therapy in Alzheimer’s disease (AD) has been hampered by narrow efficacious dose ranges and… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
Highly Cited
1999
Highly Cited
1999
Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry
This study describes the pharmacological comparison of the muscarinic partial agonists sabcomeline, xanomeline and milameline at… Expand
Highly Cited
1998
Highly Cited
1998
Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects
Activation of muscarinic m1 receptors which are coupled to the phosphoinositide (PI) second messenger transduction system is the… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE